arrow
W

Wayne C. Drevets

Johnson & Johnson
H指数:131
被引数:6.9万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Efficacy and Safety of the Selective, Brain-Penetrant P2X7 Receptor Antagonist JNJ-55308942 (Zanvipixant) in Bipolar Depression: A Phase 2a Study

选择性、可透过血脑屏障的P2X7受体拮抗剂JNJ-55308942(Zanvipixant)在双相抑郁中的疗效与安全性:一项2a期研究

2026-05-012
OAAI
Efficacy and safety of adjunctive treatment with the fatty acid amide hydrolase inhibitor JNJ-42165279 in participants with major depressive disorder with anxious distress: A double-blind, placebo-controlled, randomised study

脂肪酸酰胺水解酶抑制剂JNJ-42165279辅助治疗伴焦虑困扰的重性抑郁症患者的疗效和安全性: 一项双盲、安慰剂对照、随机研究

2026-01-290
OAAI
Effect of Esketamine on Depressive Symptoms in Adolescents With Major Depressive Disorder at Imminent Suicide Risk: A Randomized Psychoactive-Controlled Study

Esketamine对处于严重自杀风险的重性抑郁症青少年的抑郁症状的影响: 一项随机精神活性对照研究

2026-01-013
OAAI
Clinical outcomes of youth at familial risk for bipolar disorder: A 2-year longitudinal, observational study

家族性双相障碍风险青少年的临床结局:一项为期2年的纵向观察性研究

2025-10-150
OAAI
Comment on Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis

关于成人抑郁症艾斯凯特胺治疗的评论:一项PRISMA系统评价和荟萃分析

2025-10-010
PRE
Efficacy, safety, and tolerability of JNJ-61393215 (tebideutorexant), a selective orexin-1 receptor antagonist, as adjunctive treatment for major depressive disorder with anxious distress: A double-blind, placebo-controlled, randomized phase 2a study

JNJ-61393215(tebideutorexant)作为选择性食欲素-1受体拮抗剂,在伴有焦虑困扰的重度抑郁症中的疗效、安全性与耐受性:一项双盲、安慰剂对照、随机2a期研究

2025-06-010
PRE
Response to Commentaries

对评论的答复

2025-01-250
OAAI
Disturbed sex hormone milieu in males and females with major depressive disorder and low-grade inflammation

患有严重抑郁症和低度炎症的男性和女性的性激素环境紊乱

2024-07-015
OAAI